Exenatide & Ketamine: Byetta / Bydureon Compatibility
Byetta (Exenatide) (also: Bydureon, Bydureon BCise) — GLP-1 receptor agonist (type 2 diabetes)
Verdict at Tovani Health
Fully compatible with KAP; first-generation GLP-1 with the same profile as the newer drugs.
Exenatide and ketamine have no clinically significant interaction. Exenatide was the first GLP-1 receptor agonist approved (Byetta in 2005), and although newer drugs in the class (semaglutide, tirzepatide) have largely replaced it in clinical practice, real patients are still on Byetta (twice-daily) or Bydureon (once-weekly extended release) — particularly long-term diabetes patients whose regimens were stable before the newer GLP-1s came to market. The interaction profile with ketamine is identical to semaglutide: no shared mechanism, no shared metabolism, no additive cardiovascular or sedation effects. Exenatide is approved for type 2 diabetes only and never carried a suicidal-ideation warning (the FDA class rule covered chronic weight management drugs, not diabetes-only GLP-1s).
If you take Byetta regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Byetta interacts with ketamine
Exenatide agonizes the GLP-1 receptor with the same downstream effects as the rest of the class — slowed gastric emptying, enhanced insulin secretion, reduced appetite. Byetta is twice-daily subcutaneous injection; Bydureon is once-weekly extended-release. Neither shares CYP metabolism with ketamine; exenatide is cleared by glomerular filtration and proteolytic degradation. No PK or PD interaction with ketamine.
What we do at intake
Continue your normal dosing schedule (twice-daily for Byetta, weekly for Bydureon). Tell us how long you've been on it and whether GI side effects are an issue. Patients on exenatide for many years often have well-established tolerance to GLP-1 nausea, which can simplify session-day planning compared to patients newly started on a GLP-1.
Bottom line
Exenatide and ketamine have no clinically significant interaction. Exenatide was the first GLP-1 receptor agonist approved (Byetta in 2005), and although newer drugs in the class (semaglutide, tirzepatide) have largely replaced it in clinical practice, real patients are still on Byetta (twice-daily) or Bydureon (once-weekly extended release) — particularly long-term diabetes patients whose regimens were stable before the newer GLP-1s came to market. The interaction profile with ketamine is identical to semaglutide: no shared mechanism, no shared metabolism, no additive cardiovascular or sedation effects. Exenatide is approved for type 2 diabetes only and never carried a suicidal-ideation warning (the FDA class rule covered chronic weight management drugs, not diabetes-only GLP-1s).
Frequently Asked Questions
I've been on Byetta for years — do I need to switch to Ozempic before ketamine therapy?
No, there's no reason to switch on our account. If your diabetes is well-controlled on exenatide, stay on it. Ketamine therapy works the same way regardless of which GLP-1 you're taking.
Does Bydureon's once-weekly dosing affect session timing differently than Byetta's twice-daily?
Slightly. With Bydureon (weekly), GI side effects tend to be most pronounced in the first few days after injection. With Byetta (twice-daily), the GI profile is more even day-to-day. We'll plan sessions accordingly.
Did exenatide ever carry a suicidal-ideation warning?
No. Exenatide is approved for type 2 diabetes only, and the FDA class rule on SI/B warnings applied only to GLP-1s approved for chronic weight management (Saxenda, Wegovy, Zepbound). The January 2026 FDA review confirmed no class-wide signal across all GLP-1 RAs, including exenatide.
I'm being switched from Byetta to Mounjaro. Should I delay ketamine?
Not for the drug switch alone. The transition between GLP-1 RAs is generally smooth from a ketamine-compatibility standpoint. If you're expecting noticeable GI symptoms during the switch, tell us — we'll time sessions for after you've stabilized.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Byetta (Exenatide) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs. et al.. International Journal of Clinical Pharmacy. 2026. PMID: 41739406
Class-wide pharmacovigilance analysis covering exenatide and the rest of the GLP-1 receptor agonist family.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk. et al.. Biological Psychiatry. 2026. PMID: 42069105
Synthesis of GLP-1 class evidence on mood disorders and suicidality.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Ketamine PK/PD reference. Confirms ketamine's CYP3A4/CYP2B6 metabolism is fully separate from the proteolytic/renal clearance of exenatide.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 27, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.